Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas, Chromocell In Pain Pact Worth $515m-plus

This article was originally published in PharmAsia News

Executive Summary

Astellas will pay Chromocell $15m up front and could spend more than $500m on milestone fees under a license and collaboration agreement for Nav1.7 antagonists, including lead drug candidate CC8464 and backup compounds, for the treatment of neuropathic pain and other conditions.

Advertisement

Related Content

J.P. Morgan Executive Roundtable, Part 4: How Do You Determine A Drug’s Value To Patients, Payers, Partners?
J.P. Morgan Executive Roundtable, Part 3: Financing Is Difficult, But Available For Drugs That Provide Value
J.P. Morgan Executive Roundtable, Part 2: Women In Biopharma And The Path Forward
J.P. Morgan Executive Roundtable, Part 1: How To Help Women Move Into The Biopharma C-Suite

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC089201

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel